The evolution of drug-resistant malaria: the role of drug elimination half-life.
暂无分享,去创建一个
[1] W. Peters,et al. Chemotherapy and drug resistance in malaria. , 1970 .
[2] D. Hartl,et al. Principles of population genetics , 1981 .
[3] D. Falconer. Introduction to quantitative genetics. 1. ed. , 1984 .
[4] C. Curtis,et al. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[5] R. Howells,et al. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil , 1987, The Journal of pharmacy and pharmacology.
[6] T. Hughes,et al. The population dynamics of reef fishes , 1988 .
[7] A. Breckenridge,et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. , 1989, British journal of clinical pharmacology.
[8] A. Breckenridge,et al. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[9] W. Peters,et al. The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.
[10] B. Singer,et al. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[11] C. Curtis,et al. Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 4. Effects on incidence of malaria infection. , 1991, Acta tropica.
[12] S. Ward,et al. Inter-individual variation in the metabolic activation of the antimalarial biguanides. , 1991, Parasitology today.
[13] W. Watkins,et al. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[14] R. Price,et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[15] P. Olliaro,et al. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. , 1996, Parasitology today.
[16] D. Kyle,et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. , 1996, British journal of clinical pharmacology.
[17] R. Frankham. Introduction to quantitative genetics (4th edn): by Douglas S. Falconer and Trudy F.C. Mackay Longman, 1996. £24.99 pbk (xv and 464 pages) ISBN 0582 24302 5 , 1996 .
[18] I. Hastings,et al. A model for the origins and spread of drug-resistant malaria , 1997, Parasitology.
[19] O. Doumbo,et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. , 1997, The Journal of infectious diseases.
[20] J. E. Hyde,et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. , 1997, Molecular and biochemical parasitology.
[21] C. Curtis,et al. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. , 1997, Acta tropica.
[22] C. Plowe,et al. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.
[23] B. Levin,et al. The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.
[24] B G Williams,et al. Multigenic drug resistance among inbred malaria parasites , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[25] E. Lagarde,et al. Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[26] D. Arnot,et al. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[27] N. White,et al. Preventing antimalarial drug resistance through combinations. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[28] C. Plowe,et al. Kenyan Plasmodium falciparum Field Isolates: Correlation between Pyrimethamine and Chlorcycloguanil Activity In Vitro and Point Mutations in the Dihydrofolate Reductase Domain , 1998, Antimicrobial Agents and Chemotherapy.
[29] J. Koella. Costs and benefits of resistance against antimalarial drugs. , 1998, Parasitology today.
[30] R. Anderson,et al. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. , 1998, Journal of theoretical biology.
[31] C. Goodman,et al. Cost-effectiveness of malaria control in sub-Saharan Africa , 1999, The Lancet.
[32] R. Snow,et al. Averting a malaria disaster , 1999, The Lancet.
[33] R. Snow,et al. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. , 1999, Bulletin of the World Health Organization.
[34] N. White,et al. Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[35] E. Nduati,et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.
[36] P. Winstanley. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. , 2000, Parasitology today.
[37] J. Trape,et al. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. , 2000, The American journal of tropical medicine and hygiene.
[38] A. Nzila,et al. Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.
[39] A. Nzila,et al. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. , 2000, The American journal of tropical medicine and hygiene.
[40] U. d’Alessandro,et al. Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.
[41] I. Goldman,et al. Resistance to antifolates , 2003, Oncogene.